CytomX Therapeutics, Inc.

Equities

CTMX

US23284F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.22 ^USD	-3.17%		-5.43%	-21.29%

06-17	CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer	CI
05-28	Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	MT

Cytomx Therapeutics, Inc. Appoints Alan Ashworth to Board of Directors

October 04, 2021 at 08:00 am

CytomX Therapeutics, Inc. announced the appointment of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer research and a global leader in cancer therapy development, to the company’s board of directors.

Latest news about CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer	06-17	CI
Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	05-28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	05-09	MT
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	05-09	MT
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M	05-08	MT
Transcript : CytomX Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	05-08	CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	05-07	CI
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8	05-06	MT
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	04-22	MT
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	04-08	CI
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors	03-21	CI
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	03-18	CI
Transcript : CytomX Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	03-14
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	03-12	MT
North American Morning Briefing : Inflation Data Back in the Spotlight	03-12	DJ
Stocks to Watch : Oracle, Mission Produce, CytomX Therapeutics	03-11	DJ
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate	03-11	DJ
Transcript : CytomX Therapeutics, Inc., Q4 2023 Earnings Call, Mar 11, 2024	03-11
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $26.6M, vs. Street Est of $21.2M	03-11	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	01-24	CI
Transcript : CytomX Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	01-10
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	11-09	MT

Chart CytomX Therapeutics, Inc.

Duration

Period

More charts

Company Profile

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CytomX Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.22 USD

Average target price

5.318 USD

Spread / Average Target

+335.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTOMX THERAPEUTICS, INC.	-21.29%	95.06M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs